Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk. Issue 37 (September 2015)

• Record Type: Journal Article
• Authors: Hou, Qingtao; Li, Sheyu; Li, Ling; Li, Yun; Sun, Xin; Tian, Haoming; Manchia., Mirko
• Is Part Of: Medicine. Volume 94:Issue 37(2015)
• Publication Date: 2015-09
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000001268
• Languages: English
• ISSNs: 0025-7974

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Abstract</title> <p>Statin-related myopathy is an important adverse effect of statin which is classically unpredictable. The evidence of association between solute carrier organic anion transporter 1B1 (SLCO1B1) gene T521C polymorphism and statin-related myopathy risk remained controversial. This study aimed to investigate this genetic association.</p> <p>Databases of PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database, and Wanfang Data were searched till June 17, 2015. Case-control studies investigating the association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk were included. The Newcastle–Ottawa Scale (NOS) was used for assessing the quality of included studies. Data were pooled by odds ratios (ORs) and their 95% confidence intervals (CIs).</p> <p>Nine studies with 1360 cases and 3082 controls were included. Cases of statin-related myopathy were found to be significantly associated with the variant C allele (TC + CC vs TT: OR = 2.09, 95% CI = 1.27–3.43, <italic>P</italic> = 0.003; C vs T: OR = 2.10, 95% CI = 1.43–3.09, <italic>P</italic> < 0.001), especially when statin-related myopathy was defined as an elevation of creatine kinase (CK) >10 times the upper limit of normal (ULN) or rhabdomyolysis (TC + CC vs TT: OR = 3.83, 95% CI = 1.41–10.39, <italic>P</italic> = 0.008; C vs T: OR = 2.94, 95% CI = 1.47–5.89, <italic>P</italic> = 0.002). When stratified by statin type, the association was significant in individuals receiving simvastatin (TC + CC vs TT: OR = 3.09, 95% CI = 1.64–5.85, <italic>P</italic> = 0.001; C vs T: OR = 3.00, 95% CI = 1.38–6.49, <italic>P</italic> = 0.005), but not in those receiving atorvastatin (TC + CC vs TT: OR = 1.31, 95% CI = 0.74–2.30, <italic>P</italic> = 0.35; C vs T: OR = 1.33, 95% CI = 0.57–3.12, <italic>P</italic> = 0.52).</p> <p>The available evidence suggests that SLCO1B1 gene T521C polymorphism is associated with an increased risk of statin-related myopathy, especially in individuals receiving simvastatin. Thus, a genetic test before initiation of statins may be meaningful for personalizing the treatment.</p> </sec> </abstract>